SML0005
Cerivastatin sodium salt hydrate
≥98% (HPLC), HMG-CoA reductase inhibitor, powder
别名:
(3R,5S,6E)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid sodium salt hydrate, Rivastatin hydrate
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C26H33FNNaO5 · xH2O
化学文摘社编号:
分子量:
481.53 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
Cerivastatin sodium salt hydrate, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +18 to +26° in ethanol
storage condition
desiccated
color
white to tan
solubility
H2O: ≥5 mg/mL
originator
Bayer
storage temp.
2-8°C
SMILES string
O.[Na+].COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)c1-c2ccc(F)cc2)C(C)C
InChI
1S/C26H34FNO5.Na.H2O/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4;;/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32);;1H2/q;+1;/p-1/b11-10+;;/t19-,20-;;/m1../s1
InChI key
NJHMEKXCHXHQPP-PZLZTSNUSA-M
General description
Cerivastatin sodium salt hydrate belongs to the statin class of lipid lowering agents. It helps in decreasing MAP kinase activation, blocking AP-1 (activator protein-1) and NF-kB (nuclear factor-kB ) binding activity, inhibiting inflammatory responses and ameliorated renal damage. It also lowers cholesterol. It is metabolized by cytochrome P450 (CYP)3A4 and (CYP)2C8. Cerivastatin sodium salt hydrate is linked to rhabdomyolysis.
Application
Cerivastatin sodium salt hydrate has been used as a supplement in cell culture.
Cerivastatin sodium salt hydrate may be used in cell signaling studies.
Biochem/physiol Actions
Accumulated macrophages in atherosclerotic plaques result in plaque rupture and thrombus formation. Cerivastatin suppresses the growth of macrophages and decreases the expression of matrix metalloproteinases and tissue factor molecules, thus reduces acute coronary events.
Cerivastatin sodium is an HMG-CoA reductase inhibitor. HMG-CoA is a key enzyme in the production of cholesterol.
HMG-CoA reductase inhibitor
Features and Benefits
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterol-lowering effects
Park JK, et al.
Kidney International, 58(4), 1420-1430 (2000)
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
Mazzu AL, et al.
Clinical Pharmacology and Therapeutics, 68(4), 391-400 (2000)
M A Crouch
American family physician, 63(2), 309-320 (2001-02-24)
Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein cholesterol level can substantially reduce coronary events and death from coronary heart disease. In 1987
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0005-25MG | 04061833058275 |
| SML0005-5MG | 04061833058282 |